Teva considers sale of $2B active ingredients business, Bloomberg reports

Teva is considering options for its active ingredients units, and is working with advisers to consider a possible sale, Bloomberg’s Dinesh Nair reports. A deal could value the API business at about $2B, people with knowledge of the matter say. Deliberations are in the early stages, with a spokesperson saying “As part of our ongoing business conduct, we continue to regularly review our businesses.”